MedTrace Logo

A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers

NCT00687700 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2021-10-06

No results posted yet for this study

Summary

Study will investigate the pharmacodynamics of a dual pharmacophore in which a combination of GSK961081 and Propanolol is used to give a total effect of bronchodilation.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK961081

GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.

DRUG

GSK961081 matching placebo

GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.

DRUG

Propranolol

Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.

DRUG

Propranolol matching placebo

Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-10
Primary Completion
2008-05-27
Completion
2008-05-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687700 on ClinicalTrials.gov